APM
APGE icon

Avidity Partners Management’s Apogee Therapeutics APGE Stock Holding History

Avidity Partners Management’s Portfolio APGE Stock Details APGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-65,000
Closed -$2.82M – 45
2025
Q2 		$2.82M Buy
+65,000
New +$2.47M 0.56% 43
2024
Q4 		– Sell
-154,000
Closed -$9.05M – 64
2024
Q3 		$9.05M Sell
154,000
-333,000
-68% -$16M 0.46% 59
2024
Q2 		$19.2M Buy
487,000
+102,107
+27% +$4.96M 0.81% 46
2024
Q1 		$25.6M Buy
+384,893
New +$16.8M 0.82% 42

Other funds holding APGE

VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Avidity Partners Management's APGE Position: Q3 2025 in Review

Avidity Partners Management sold out of Apogee Therapeutics (APGE) in Q3 2025, closing a stake of 65,000 shares — an estimated $2.82M sold.

Avidity Partners Management first reported a position in APGE in Q1 2024 and held it in 4 quarters. The position peaked at $25.6M in Q1 2024. 174 funds tracked by Wall St. Rank hold APGE as of Q3 2025.

  • Avidity Partners Management reported no remaining Apogee Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Avidity Partners Management sold 65,000 Apogee Therapeutics shares in Q3 2025, an estimated $2.82M.
  • Avidity Partners Management first reported a position in Apogee Therapeutics in Q1 2024 and held it in 4 quarters.
  • Avidity Partners Management's Apogee Therapeutics position peaked at $25.6M in Q1 2024.
  • 174 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q3 2025.

Based on Avidity Partners Management's 13F filing for Q3 2025, filed 14 Nov 2025.